New drug combo aims to tackle Hard-to-Treat myeloma

NCT ID NCT05927571

Recruiting now Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 06, 2026 · Updated 5 times

Summary

This early-stage trial is testing whether combining two drugs, cevostamab and elranatamab, is safe and tolerable for people with multiple myeloma that has returned or not responded to prior treatments. About 120 participants will receive the drugs, and researchers will monitor side effects and determine the best dose for future studies. The goal is to find a new option for this difficult-to-treat blood cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cevostamab and elranatamab (two cancer drugs given by infusion or injection)
What this could lead to: If this combination works, it could offer a new treatment option for people with multiple myeloma that has come back or stopped responding to other therapies.
What could go wrong: This is an early Phase 1 trial, so the main goal is safety, not proof of effectiveness. The drugs may cause side effects like cytokine release syndrome, and the combination might not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

Asan Medical Center.
RECRUITING

Seoul, 05505, South Korea
Calvary Mater Newcastle
RECRUITING

Waratah, New South Wales, 2298, Australia
Hadassah University Hospital - Ein Kerem
RECRUITING

Jerusalem, 9112001, Israel
Rambam Health Care Campus
RECRUITING

Haifa, 3109600, Israel
Royal Adelaide Hospital;Haematology Clinical Trials Unit
RECRUITING

Adelaide, South Australia, 5000, Australia
Royal Prince Alfred Hospital
RECRUITING

Camperdown, New South Wales, 2050, Australia
Samsung Medical Center - PPDS
RECRUITING

Seoul, 06351, South Korea
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
Severance Hospital, Yonsei University Health System
RECRUITING

Seoul, 03722, South Korea
St. Vincent's Hospital Melbourne
RECRUITING

Melbourne, Victoria, 3065, Australia
Tel Aviv Sourasky Medical Center PPDS
RECRUITING

Tel Aviv, 6423906, Israel
The Alfred Hospital
RECRUITING

Prahan, Victoria, 3181, Australia
The Catholic University of Korea - Seoul St. Mary's Hospital (Kangnam St. Mary's Hospital)
RECRUITING

Seocho, 06591, South Korea
The Chaim Sheba Medical Center - PPDS
RECRUITING

Ramat Gan, Central District, 5262100, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.